Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2022 | Session highlights: closing the gap of basic and clinical research in AL and ATTR amyloidosis

Vittorio Bellotti • 5 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Vittorio Bellotti, MD, PhD, University of Pavia, Pavia, Italy, briefly highlights some of the topics that were presented in a session at ISA 2022, which focused on closing the gap of basic and clinical research in amyloidosis. Dr Bellotti also discusses the value of generating and improving models used to understand the biology of this disease. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Vittorio Bellotti

Bridging the gap between in vitro and in vivo models of amyloid formation 1:15
Bridging the gap between in vitro and in vivo models of amyloid formation
Vittorio Bellotti • 5 Sep 2022

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals